There is one ongoing phase 2 clinical trial that aims to investigate the efficacy, safety, pharmacokinetics, and pharmacodynamics of STI-3031 (anti-PDL1 antibody) in patients with selected relapsed or refractory (R/R) malignancies of the biliary tract(intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, or gallbladder cancer), extra nodal NK/T-cell lymphoma (ENKTL), peripheral T-cell lymphomas (PTCL), and diffuse large B cell lymphoma [41]. This evidence concerns the gene CD274 and diffuse large B-cell lymphoma.